详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Evaluation of astatine-211-labeled octreotide as a potential radiotherapeutic agent for NSCLC treatment.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Nuclear Medicine, Shanghai 10th People’s Hospital, Tongji University School of Medicine, Shanghai 200072, PR China [2]Key Laboratory of Radiation Physics and Technology, Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, PR China [3]Department of Nuclear Medicine, Sichuan Huaxi Hospital, Sichuan University, Chengdu 610000, PR China

出处：

DOI：

ISSN：

关键词： Astatine-211 Octreotide Alpha therapy Non-small cell lung cancer

摘要：

Octreotide is a somatostatin (SST) analogue currently used in the treatment of neuroendocrine tumors (NETs) with high binding affinity for the somatostatin receptor-2 (SSTR2) that is also overexpressed in non-small cell lung cancer cell (NSCLC). Alpha-particle-emitting astatine-211 (211At) is a promising radionuclide with appropriate physical and chemical properties for use in targeted anticancer therapies. To obtain an additional pharmacological agent for the treatment of NSCLC, we present the first investigation of the possible use of 211At-labeled octreotide as a potential alpha-radionuclide therapeutic agent for NSCLC treatment. 211At-SPC-octreotide exhibited observable higher uptake in lung, spleen, stomach and intestines than in other tissues. Through histological examination, 211At-SPC-octreotide demonstrated much more lethal effect than control groups (PBS, octreotide and free 211At). These promising preclinical results suggested that 211At labeled octreotide deserved to be further developed as a new anticancer agent for NSCLC. Copyright © 2018 Elsevier Ltd. All rights reserved.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 3 区医学

小类 | 3 区生化与分子生物学 3 区药物化学 3 区有机化学

最新[2023]版：

大类 | 3 区医学

小类 | 2 区有机化学 3 区生化与分子生物学 3 区药物化学

第一作者：

第一作者机构： [1]Department of Nuclear Medicine, Shanghai 10th People’s Hospital, Tongji University School of Medicine, Shanghai 200072, PR China

共同第一作者：

通讯作者：

通讯机构： [1]Department of Nuclear Medicine, Shanghai 10th People’s Hospital, Tongji University School of Medicine, Shanghai 200072, PR China [*1]Department of Nuclear Medicine, Shanghai 10th People’s Hospital, Tongji University School of Medicine, 301 Middle Yanchang Road, Shanghai 200072, PR China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]211At radiolabeled APBA-FAPI for enhanced targeted-alpha therapy of glioma [2]Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer [3]A new strategy for facile and rapid separation of astatine-211 from nitric acid medium [4]KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review [5]A new strategy for facile and rapid separation of astatine-211 from nitric acid medium [6]A new strategy for facile and rapid separation of astatine-211 from nitric acid medium [7]Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer [8]Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using 211At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response [9]Cell-type-specific alternative polyadenylation promotes oncogenic gene expression in non-small cell lung cancer progression [10]RSPH14 regulates the proliferation, cell cycle progression, and apoptosis of non-small cell lung cancer cells